Description
Added on the 17/01/2016 18:25:59 - Copyright : Euronews EN
One person has died and five others are in a serious condition after taking part in a French drug trial of an experimental painkiller. Rough Cut - Subtitled (no reporter narration).
Bayonne, Jul 8 (EFE / EPA) .- Thousands of people participated in a white march on Wednesday as a tribute to Philippe Monguillot, a bus driver who was declared brain dead after being attacked by a group of people whom he refused to let on the bus for not wearing a mask.(Camera: CAROLINE BLUMBERG) FOOTAGE SHOWS THE WHITE MARCH IN HONOR OF BUS DRIVER PHILIPPE MONGUILLOT IN BAYONNE, FRANCE.
The trial of a vast international cocaine and cannabis trafficking operation, for which more than 100 people have been summoned to appear before the Brussels court, was adjourned and the opening of the proceedings is now set for 18 December, the court has announced. IMAGES
Trier (Germany), Aug 19 (EFE / EPA).- (Camera: Ronald Wittek) This Thursday begins the trial against the 51-year-old German arrested after the multiple outrages that occurred in the city of Trier (western Germany) in December 2020 and that left five dead, including a nine-month-old baby, and fifteen wounded.FOOTAGE OF JOURNALISTS WAITING FOR THE START OF THE TRIAL IN FRONT OF THE TREVERIS DISTRICT COURT.
Paris, Apr 12 (EFE/EPA).- (Camera: Yoan Valat) One person has been killed and another seriously injured after an armed assailant opened fire outside a Paris hospital on Monday before fleeing the scene, local media reported.FOOTAGE OF THE AREA OF THE ATTACK.
The FDA approved remdesivir as a treatment for severe COVID-19 cases last month. This is after granting emergency authorization in May, reports Business Insider. But on Thursday, the WHO announced it will not recommend the drug's use for COVID-19 patients. "There is currently no evidence that it improves survival or the need for ventilation," the organization said. Remdesivir was the first coronavirus treatment to receive emergency authorization from the FDA. With Pfizer and Moderna's vaccines on the horizon, there is less of a need for weaker treatments.
|
Support : Technical 
- Content 
- Editors 
